本文選題：艾滋病 + 卡波西肉瘤��； 參考：《新疆醫(yī)科大學》2014年碩士論文

【摘要】：目的：分析新疆艾滋病（AIDS）相關卡波西肉瘤（KS）患者的臨床特征，探討CD4+T淋巴細胞計數(shù)、高效聯(lián)合抗反轉錄病毒治療（HAART）及系統(tǒng)性化療等對患者預后的影響。方法：采用回顧性研究的方法，收集2008年1月至2013年6月新疆維吾爾自治區(qū)第六人民醫(yī)院收治的70例艾滋病相關卡波西肉瘤（AIDS-KS）患者的臨床資料，從人群特點、病變部位及范圍、KS進展情況、CD4+T淋巴細胞計數(shù)、合并機會性感染、治療及預后等方面進行總結分析，并按照治療方法不同分為5組：HAART組（A組）、HAART+化療組（B1組）、化療+HAART組（B2組）、化療組（C組）、觀察組（D組），比較不同治療組的療效及預后。結果：70例中維吾爾族66例（94.29%），平均年齡（39.7±10.4）歲，，男女比例2.5：1。基線CD4+T淋巴細胞計數(shù)中位數(shù)M為152.5個/μl，四分位數(shù)間距Q為231.2個/μl。A組及B1組治療后CD4+T淋巴細胞計數(shù)增加，P值分別為0.003和0.007，差異有統(tǒng)計學意義； C組及D組治療后CD4+T淋巴細胞計數(shù)下降，P值分別為0.045和0.028，差異有統(tǒng)計學意義。5組中D組病死率最高（22.2%）。A組45.5%出現(xiàn)卡波西肉瘤相關免疫重建炎性反應綜合癥（KS-IRIS），該組2例死亡原因均與KS-IRIS有關。結論:新疆艾滋病相關卡波西肉瘤多發(fā)生于中青年，以維吾爾族男性多見，病灶部位多樣化，部分呈快速進展。B1組采取先開始高效聯(lián)合抗反轉錄病毒治療續(xù)以系統(tǒng)性化療的治療方法，降低了卡波西肉瘤相關免疫重建炎性反應綜合癥的發(fā)生率，明顯改善患者預后，療效較好。
[Abstract]:Objective: to analyze the clinical features of patients with KPS associated with AIDS in Xinjiang, and to explore the effect of CD4 T lymphocyte count, highly effective antiretrovirus therapy and systemic chemotherapy on the prognosis of the patients. Methods: from January 2008 to June 2013, 70 AIDS-KS patients with AIDS-KS were collected from the sixth people's Hospital of Xinjiang Uygur Autonomous region. The location and extent of KS, CD4 T lymphocyte count, combined with opportunistic infection, treatment and prognosis were summarized and analyzed. They were divided into 5 groups according to different treatment methods: group A, group B 1, group HAART, group B 2, group C, observation group D, the curative effect and prognosis of different treatment groups were compared. Results among 70 cases, 66 cases of Uygur nationality had an average age of 39.7 鹵10.4 years, and the ratio of male to female was 2.5: 1. The median CD4 T lymphocyte count M was 152.5 / 渭 l, the quartile interval Q was 231.2 / 渭 l.A group and B1 group after treatment, the increase of CD4 T lymphocyte count was 0.003 and 0.007 respectively, there was significant difference between C group and D group. The decrease of T lymphocyte count in CD4 group was 0.045 and 0.028, respectively. The difference was statistically significant. The mortality of group D was the highest (22. 2%). Group A (45. 5%) had KS-IRIS-associated sarcoma-associated inflammatory response syndrome (KS-IRISS). The causes of death in this group were all related to KS-IRIS. Conclusion: AIDS-related Kaposi sarcoma mostly occurs in young and middle-aged people, most of them in Uygur nationality, and the foci are diverse. Partial rapid progress. Group B1 was treated with high efficiency and antiretrovirus therapy followed by systemic chemotherapy, which reduced the incidence of Kaposi sarcoma-associated immunoreconstructive inflammatory response syndrome and significantly improved the prognosis of the patients. The curative effect is better.
【學位授予單位】：新疆醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R512.91

【參考文獻】

相關期刊論文 前10條

1 買買提艾力·吾布力;宋江美;佐合拉·吐爾地;阿地力;潘珂君;張躍新;;新疆地區(qū)40例艾滋病患者臨床特點分析[J];中國感染控制雜志;2008年06期

2 李亮;孫江紅;趙華;;以頭頸部卡波西肉瘤為首發(fā)癥狀的艾滋病1例[J];臨床耳鼻咽喉頭頸外科雜志;2012年03期

3 普雄明，石得仁，沈大為;新疆Kaposi肉瘤組織內巨細胞病毒抗原的檢測報告[J];臨床皮膚科雜志;1994年02期

4 盧斯?jié)h;岑玉文;易俊卿;;艾滋病相關型卡波西肉瘤1例[J];嶺南皮膚性病科雜志;2009年01期

5 郭瑞章;馮艷玲;盧洪洲;張仁芳;沈銀忠;江雪艷;;艾滋病合并多部位Kaposi′s肉瘤一例[J];中國全科醫(yī)學;2010年20期

6 鄭軍;林兆全;;口腔頜面部卡波西肉瘤VEGF及CD34的表達及意義[J];實用口腔醫(yī)學雜志;2010年05期

7 譚曉華;楊磊;李冬妹;郭淑霞;李鋒;秦江梅;張萬江;謝建新;芮東升;普雄明;;17例新疆經典型卡波西肉瘤患者血清細胞因子水平和病毒感染相關性分析[J];中國艾滋病性病;2008年01期

8 周新剛;刀文斌;張亮;郎振為;;全身播散性艾滋病相關型卡波西肉瘤一例[J];中國艾滋病性病;2010年06期

9 楊培榮;譚曉華;郭淑霞;楊磊;曾妍;付碧石;王林定;陳彬;;新疆某市吸毒人群血清KSHV感染調查分析[J];現(xiàn)代預防醫(yī)學;2010年01期

10 張風華;黃小魯;;放射治療經典型卡波西肉瘤45例臨床分析[J];新疆醫(yī)學;2011年07期

本文編號：1952235